Vaxcyte (PCVX) Preferred Shares Issued (2020)

Vaxcyte (PCVX) reported Preferred Shares Issued of $4000.0 for Q2 2020, down 100.0% quarter-over-quarter from $109.9 million in Q1 2020.

Vaxcyte (PCVX) Preferred Shares Issued (2020) Analysis & Trends

Vaxcyte (PCVX) has 1 years of Preferred Shares Issued data on file, last reported at $4000.0 in Q2 2020.

Preferred Shares Issued for Q2 2020 came in at $4000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $109.9 million (changed N/A YoY), and the FY2020 annual result was $109.9 million, up 158.54% from the prior year.
Preferred Shares Issued slipped to $4000.0 in Q2 2020 per PCVX's latest filing, from $109.9 million in the prior quarter.
Over five years, Preferred Shares Issued peaked at $109.9 million in Q1 2020 and troughed at $4000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares Issued (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Vaxcyte	6.34 Bn	6.34 Bn	-	-

Download Data